Navigation Links
Cell Biosciences Signs Agreement to Acquire Alpha Innotech
Date:9/8/2009

SANTA CLARA, Calif., Sept. 8 /PRNewswire/ -- Cell Biosciences, Inc. and Alpha Innotech Corp. (OTC Bulletin Board: APNO) today announced that they have entered into a definitive agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for $1.50 per share or approximately $17.9 million in cash. This acquisition would significantly expand Cell Biosciences' protein analysis business to include a global infrastructure and a broad protein analysis product portfolio.

Founded in 1992, Alpha Innotech is a pioneer in the use of high-sensitivity digital imaging systems for genomic and proteomic research. The company offers a broad range of best-in-class products, from entry-level gel documentation systems to premier systems for multiplexed fluorescence and proteomics applications. The company has sold over 10,000 systems worldwide. In 2008, Alpha Innotech achieved revenues of $17.6 million and was profitable on both an operating and a net income basis. Alpha Innotech employs 62 people, primarily at its San Leandro, California headquarters.

Cell Biosciences is a private life sciences company established in 2004, and is focused on revolutionizing protein and biomarker research. The company's lead product is the CB1000, a nanofluidic immunoassay platform designed for ultrasensitive detection and characterization of oncoproteins and other signaling proteins in ultra-small biological samples, such as small tumor biopsies and stem cells. Cell Biosciences is headquartered in Santa Clara, California and has 49 employees located in North America and Europe.

The combination of Cell Biosciences and Alpha Innotech would create a global protein analysis business with a broad product line featuring both traditional and novel protein analysis technologies. Virtually every protein research laboratory worldwide would become a potential customer for the combined entity.

Commentin
'/>"/>

SOURCE Cell Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
2. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
3. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
4. SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies
5. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
6. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
7. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
8. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
9. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
10. Ingenuitys Technology Powers BD Cell Pathways Tool on New BD Biosciences Website
11. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
(Date:7/24/2014)... natural and synthetic processes prefer to settle into ... energyit is within the realm of non-equilibrium conditions ... changes in energy and phases, such as temperature ... allow humans to regulate their body temperature, airplanes ... seismic activity. , But even though these ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... 1000 balances – 4 steps – ... weighing needs and expertly narrows down the mass of ... or even terminals. , First, select the working ... select readability instead) and define the accuracy – it’s ... narrows down the list to models that fit best ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... Lumidigm, Inc. is proud to announce that its ... technologies and products recognized by Popular Science as ... Venus product is the first high-volume multispectral imaging ... ease of integration, the Venus fingerprint sensor features ...
... LAUSANNE, Switzerland and BANGALORE, India, November ... biopharmaceutical development,specialist that focuses on serious ... Discovery Technologies Ltd (Aurigene), a,Bangalore-based fully ... molecule,and peptide drug discovery and development ...
... (OTC Bulletin Board: SYMD) announced today that it has ... membrane intended to prevent post-operative adhesions in nasal and ... and sinus procedures performed annually in the United States. ... P. Hickey, SyntheMed,s President & CEO stated, "SinusShield represents ...
Cached Biology Technology: Lumidigm Biometric Sensor Included in Popular Science Best of What's New for 2008 : Venus Series Fingerprint Sensor Called a Breakthrough Product by the World's Largest Science and Technology Magazine 2 Lumidigm Biometric Sensor Included in Popular Science Best of What's New for 2008 : Venus Series Fingerprint Sensor Called a Breakthrough Product by the World's Largest Science and Technology Magazine 3Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 3SyntheMed Announces FDA Clearance of SinusShield(TM) 2
(Date:7/25/2014)... bifda (SB) is a complex congenital central nervous ... closing of the neural tubes during the embryonic ... urinary and fecal incontinence and neurocognitive retardation. Such ... quality of life. Researchers at Ankara Physical Medicine ... the functional performance in children with SB, using ...
(Date:7/25/2014)... first time, Spanish researchers have detected an unknown interaction ... cells are introduced into a droplet of salt water ... chloride crystallisation to create biomineralogical biosaline 3D morphologically complex ... material, bacteria are revived. The discovery was made by ... cover of the Astrobiology journal and may ...
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, ... devices, has cut emergency room wait times by an ... (UCSD) Medical Center, according to a recent study published ... Departments are using the suite to access data from ... defibrillators. "Using Geneva,s technology platform we have ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... The leaking of environmentally damaging pollutants into our waters ... mathematical algorithm, according to researchers. Presenting their research ... Problems , the researchers, from Universit de Technologie ... avoid environmental catastrophes by identifying the exact location where ...
... renowned biologist and population geneticist, has been named founding ... This newly created position will further strengthen GW,s role ... region and nationally. As director, Dr. Crandall ... Institute and direct the development and implementation of research ...
... as an important predictor of survival among human patients with ... Veterinary Medicine at Tufts University have developed two surveys that ... of life for dogs and cats with heart disease. ... (Cats, Assessment Tool for Cardiac Health), the surveys ask owners ...
Cached Biology News:Maths formula leads researchers to source of pollution 2GW announces creation of Computational Biology Institute to conduct integrated research 2GW announces creation of Computational Biology Institute to conduct integrated research 3GW announces creation of Computational Biology Institute to conduct integrated research 4New tools for evaluating quality of life for cats, dogs with heart disease 2
...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... dsRNA Marker consists of ten double-stranded RNAs, ... 400, 500 and 1,000 base pairs. The ... for determinating sizes of double-stranded RNAs. A ... dsRNA Marker is adjusted to approximately 25 ...
... antibody raised against a partial ... Immunogen: HD (NP_002102, 81 ... recombinant protein with GST tag. ... NM_002111 ...
Biology Products: